Rapid P2Y12 inhibition: still an unmet medical need.
Johanne
J
Silvain
Gilles
G
Montalescot
D015906:Angioplasty, Balloon, Coronary; D000077144:Clopidogrel; D005260:Female; D006331:Heart Diseases / Q000628:therapy*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D052999:Quinazolinones / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D058925:Receptors, Purinergic P2Y12 / Q000187:drug effects*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D052999:Quinazolinones; D058925:Receptors, Purinergic P2Y12; D013449:Sulfonamides; C549473:elinogrel; D000077144:Clopidogrel; D013988:Ticlopidine